

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 110 957 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

27.06.2001 Bulletin 2001/26

(21) Application number: 99811207.2

(22) Date of filing: 24.12.1999

(51) Int Cl.7: **C07D 277/64**, C07D 263/56,
C07D 235/16, C07D 417/06,
C07D 417/14, C07D 413/06,
C07D 403/06, A61K 31/4184,
A61K 31/428, A61K 31/423,
A61P 25/00

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(71) Applicant: Applied Research Systems ARS

Holding N.V.

Curacao (AN)

(72) Inventors:

- Halazy, Serge
74100 Vétraz-Monthoux (FR)

• Church, Dennis

1291 Commugny (FR)

• Camps, Montserrat

1290 Versoix (CH)

• Gaillard, Pascale

74160 St. Julien-en-Genevois (FR)

• Gotteland, Jean-Pierre

74160 Beaumont (FR)

(74) Representative: Hassa, Jürgen


Serono International S.A.,

12, Chemin des Aulx

1228 Plan-les-Ouates (CH)

(54) Benzazole derivatives and their use as JNK modulators

(57) The present invention is related to benzazole derivatives according to formula I



I

wherein

X is O, S or NR⁰.

G is selected from the group comprising or consisting of unsubstituted or substituted aryl or heteroaryl substituents, unsubstituted or substituted 3-8-membered saturated or unsaturated ring systems containing at least one heteroatom selected from N, O or S; said 3-8-membered ring system may be fused with a substituted or unsubstituted aryl or heteroaryl system thus providing a bicyclic system;

notably for use as pharmaceutically active compounds. Said benzazole derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK2 and/or 3. The present invention is furthermore related to certain novel benzazole derivatives of formula I.

EP 1 110 957 A1

Formulation 4 - Tablets

[0103] A benzazole compound of formula I is admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 450-900 mg tablets (150-300 mg of active benzazole compound) in a tablet press.

Formulation 5 - Injection

[0104] A benzazole compound of formula I is dissolved in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg/ml.

Example 6 : Biological assays

[0105] **JNK2 and 3 In vitro assays:** JNK3 and/or 2 assays are performed in 96 well MTT plates, by incubation of 0.5 µg of recombinant, pre-activated GST-JNK3 with 1 µg of recombinant, biotinylated GST-c-Jun and 2 µM $^{33}\gamma$ -ATP (2 nCi/µl), in the presence or absence of benzazole inhibitors and in a reaction volume of 50 µl containing 50 mM Tris-HCl, pH 8.0; 10 mM MgCl₂; 1 mM Dithiothreitol, and 100 µM NaVO₄. The incubation is performed for 120 min. at R.T and stopped upon addition of 200 µl of a solution containing 250 µg of Streptavidine-coated SPA beads (Amersham, Inc.), 5 mM EDTA, 0.1% Triton X-100 and 50 µM ATP, in phosphate saline buffer. After incubation for 60 minutes at RT, beads are sedimented by centrifugation at 1500 x g for 5 minutes, resuspended in 200 µl of PBS containing 5 mM EDTA, 0.1% Triton X-100 and 50 µM ATP and the radioactivity measured in a scintillation β counter, following sedimentation of the beads as described above. By substituting GST-c Jun for biotinylated GST- γ ATF₂ or myelin basic protein, this assay can be used to measure inhibition of preactivated p38 and ERK MAP Kinases, respectively.

[0106] **Sympathetic Neuron Culture and Survival Assay :** Sympathetic neurons from superior cervical ganglia (SCG) of newborn rats (p4) are dissociated in dispase, plated at a density of 10⁴ cells/cm² in 48 well MTT plates coated with rat tail collagen, and cultured in Leibowitz medium containing 5% rat serum, 0.75 µg/ml NGF 7S (Boehringer Mannheim Corp., Indianapolis, IN.) and arabinosine 10⁵M. Cell death is induced at day 4 after plating by exposing the culture to medium containing 10 µg/ml of anti NGF anti-body (Boehringer Mannheim Corp., Indianapolis, IN.) and no NGF or arabinosine, in the presence or absence of benzazole inhibitors. 24 hours after cell death induction, determination of cell viability is performed by incubation of the culture for 1 hour, at 37°C in 0.5 mg/ml of 3-(4,5-dimethylthiazol-2-yl)2,5 diphenyl tetrazolium bromide (MTT). After incubation in MTT cells are resuspended in DMSO, transferred to a 96 MTT plate and cell viability is evaluated by measuring optical density at 590 nm.

Biological Results


[0107] The activities of the benzazole derivatives claimed in the formula I were assessed using the above described *in vitro* and *in vivo* biologicals assays. Representative values are given in the table shown below:

Compound	JNK3	JNK2	p38	ERK2
1	290	500	>30000	>30000
5	400	1200	>30000	>30000
15	70	210	>30000	>30000
20	950	2300	>30000	>30000
28	960	1800	>30000	>30000
40	105	450	>30000	>30000

[0108] The values indicated in respect of JNK2 and 3, p38 and ERK2 refer to the IC₅₀ (nM), i.e. the amount necessary to achieve 50% inhibition of said target (e.g. JNK2 or 3). AS# denotes an exemplary test compound as set out with its number in the above examples. From the above table it could be derived that said test compounds according to formula I do have a significant effect both on JNK2 and more notably on JNK 3, but virtually no effect onto p38 and ERK2, thus delivering a quite selective inhibitory effect.

Claims

1. Benzazole derivatives according to formula I



I

as well as its tautomers, its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

X is O, S or NR⁰, with R⁰ being H or an unsubstituted or substituted C₁-C₆ alkyl;


G is selected from the group comprising or consisting of unsubstituted or substituted aryl or heteroaryl substituents, unsubstituted or substituted 3-8-membered saturated or unsaturated ring systems containing at least one heteroatom selected from N, O or S; said 3-8-membered ring system may be fused with a substituted or unsubstituted aryl or heteroaryl system thus providing a bicyclic system;

R¹ is selected from the group comprising or consisting of hydrogen, unsubstituted or substituted C₁-C₆-alkoxy, unsubstituted or substituted C₁-C₆-thioalkoxy, unsubstituted or substituted C₁-C₆-alkyl, unsubstituted or substituted C₂-C₆-alkenyl, unsubstituted or substituted C₂-C₆-alkynyl, primary, secondary or tertiary amino groups, aminoacyl, aminocarbonyl, unsubstituted or substituted C₁-C₆ alkoxy carbonyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, sulfonyl, sulfonamide, unsubstituted or substituted hydrazides;


R² is selected from the group comprising or consisting of hydrogen, unsubstituted or substituted C₁-C₆-alkyl, unsubstituted or substituted C₂-C₆-alkenyl, unsubstituted or substituted C₂-C₆-alkynyl, unsubstituted or substituted C₁-C₆-alkyl-aryl, unsubstituted or substituted aryl or heteroaryl, unsubstituted or substituted C₁-C₆-alkyl-heteroaryl, -C(O)-OR³, -C(O)-R³, -C(O)-NR³R³, -(SO₂)R³, with

R³ and R³ being independently selected from the group comprising or consisting of hydrogen, unsubstituted or substituted C₁-C₆ alkyl, unsubstituted or substituted C₂-C₆ alkenyl, unsubstituted or substituted C₂-C₆ alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted C₁-C₆-alkyl aryl, unsubstituted or substituted C₁-C₆-alkyl heteroaryl,

with the proviso that if X is S or NH, while R¹ and R² are both H, G shall not be




with the further proviso that if X is S, R¹ and R² are both H, G shall not be




EP 1 110 957 A1

with R^{1'} being H, methyl or —OCH₃; R^{2'} and R^{3'} being H or methyl and R^{4'} being H, methyl or —OCH₃,
with the further proviso that if X is S or O, R¹ and R² are both H, G shall not be



with R^{2'} being H, lower alkyl, lower alkoxy or halogen and with n = 1-4,
with the final proviso that if X is O, S or NR, with R being H, C₁-C₄ alkyl or aryl, G shall not be a 4-diazo-, or
4-diazoniumphenyl group.

2. Benzazole derivatives according to formula I



I

as well as its tautomers, its geometrical isomers, its optically active forms as enantiomers, diastereomers and its
racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

X is O, S or NR⁰, with R⁰ being H or an unsubstituted or substituted C₁-C₆ alkyl;


G is selected from the group comprising or consisting of unsubstituted or substituted aryl or heteroaryl sub-
stituents, unsubstituted or substituted 3-8-membered saturated or unsaturated ring systems containing at least
one heteroatom selected from N, O or S; said 3-8-membered ring system may be fused with a substituted or
unsubstituted aryl or heteroaryl system thus providing a bicyclic system;

R¹ is selected from the group comprising or consisting of hydrogen, unsubstituted or substituted C₁-C₆-alkoxy,
unsubstituted or substituted C₁-C₆-thioalkoxy, unsubstituted or substituted C₁-C₆-alkyl, unsubstituted or sub-
stituted C₂-C₆-alkenyl, unsubstituted or substituted C₂-C₆-alkynyl, primary, secondary or tertiary amino groups,
aminoacyl, aminocarbonyl, unsubstituted or substituted C₁-C₆ alkoxycarbonyl, unsubstituted or substituted
aryl, unsubstituted or substituted heteroaryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, sulfonyl, sul-
fonamide, unsubstituted or substituted hydrazides;

R² is selected from the group comprising or consisting of hydrogen, unsubstituted or substituted C₁-C₆-alkyl,
unsubstituted or substituted C₂-C₆-alkenyl, unsubstituted or substituted C₂-C₆-alkynyl, unsubstituted or sub-
stituted C₁-C₆-alkyl-aryl, unsubstituted or substituted aryl or heteroaryl, unsubstituted or substituted C₁-C₆-
alkyl-heteroaryl, -C(O)-OR³, -C(O)-R³, -C(O)-NR³R^{3'}, -(SO₂)R³, with


R³ and R^{3'} being independently selected from the group comprising or consisting of hydrogen, unsubstituted
or substituted C₁-C₆ alkyl, unsubstituted or substituted C₂-C₆ alkenyl, unsubstituted or substituted C₂-C₆ alky-
nyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted C₁-
C₆-alkyl aryl, unsubstituted or substituted C₁-C₆-alkyl heteroaryl,

with the proviso that if X is S or O, R¹ and R² are both H, G shall not be



with R^2 being H, lower alkyl, lower alkoxy or halogen and with $n = 1-4$, for use as a medicament.


3. A benzazole derivative according to claim 1 or 2, wherein R^2 is hydrogen, an unsubstituted or substituted C_1-C_6 alkyl, an unsubstituted or substituted C_1-C_6 alkylaryl or C_1-C_6 alkyl-heteroaryl group, $-C(O)-R^3$, $-C(O)-NR^3R^3$, $-(SO_2)R^3$, whereby R^3 and R^3 are as above defined.
4. A benzazole derivative according to any of the preceding claims, wherein R^2 is hydrogen and R^1 , X and G are as above defined.
5. A benzazole derivative according to any of the preceding claims, wherein R^1 is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl or C_1-C_6 alkoxy.
6. A benzazole derivative according to claim 4, wherein R^3 and R^3 are selected from the group consisting of hydrogen, C_1-C_6 alkyl, aryl, heteroaryl, C_1-C_6 -alkyl aryl, C_1-C_6 -alkyl heteroaryl.
7. A benzazole derivative according to claim 6, wherein R^3 and R^3 is hydrogen or C_1-C_6 alkyl.
8. A benzazole derivative according any of the preceding claims, wherein said aryl or heteroaryl group is substituted with at least one substituent selected from the group consisting of unsubstituted or substituted C_1-C_6 alkyl, unsubstituted or substituted C_1-C_6 alkoxy, unsubstituted or substituted C_2-C_6 alkenyl, unsubstituted or substituted alkynyl, amino, aminoacyl, aminocarbonyl, unsubstituted or substituted C_1-C_6 -alkoxycarbonyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, sulfonyl, C_1-C_6 alkoxythio.
9. A benzazole derivative according to any of the preceding claims, wherein G is an unsubstituted or substituted pyrimidinyl group.
10. A benzazole derivative according to claim 9, wherein G is a pyrimidinyl group



- wherein L is selected from the group comprising or consisting of hydrogen, unsubstituted or substituted C_1-C_6 alkyl, unsubstituted or substituted C_1-C_6 alkoxy, unsubstituted or substituted C_1-C_6 thioalkoxy, unsubstituted or substituted C_2-C_6 alkenyl, unsubstituted or substituted C_2-C_6 alkynyl, primary, secondary or tertiary amino groups, aminoacyl, aminocarbonyl, amino- (C_1-C_{10}) alkyl, amino- unsubstituted or substituted (C_1-C_{10}) -alkyl-aryl, amino-unsubstituted or substituted (C_1-C_{10}) alkylheteroaryl, unsubstituted or substituted C_1-C_6 alkoxycarbonyl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, sulfonyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted 3-8 membered cycloalkyl, optionally containing at least one heteroatom selected from N, O, S, and unsubstituted or substituted hydrazido groups.
11. A benzazole derivative according to claim 10, wherein L is a substituted or unsubstituted (C_1-C_{10}) -alkyl group.
12. A benzazole derivative according to claim 10, wherein L is a group $-N(R^a, R^b)$ or $-OR^a$, with R^a and R^b being each independently selected from the group consisting of H, unsubstituted or substituted (C_1-C_{10}) -alkyl, unsubstituted or substituted C_1-C_6 alkyl-aryl, unsubstituted or substituted C_1-C_6 -alkyl-heteroaryl, unsubstituted or substituted

aryl or heteroaryl and unsubstituted or substituted 4-8 membered saturated or unsaturated cycloalkyl.

13. A benzazole derivative according to claim 12 wherein L is selected from



wherein n is 1 to 10, preferably 1 to 6

25 R⁵ and R^{5'} are independently selected from each other from the group consisting of H, substituted or unsubstituted C₁-C₁₀ alkyl, substituted or unsubstituted aryl or heteroaryl, substituted or unsubstituted C₁-C₆ alkyl-aryl and substituted or unsubstituted C₁-C₆-alkyl-heteroaryl.

14. A benzazole derivative according to claim 13, wherein R^{5'} is an unsubstituted or substituted imidazolyl.

30 15. A benzazole derivative according to any of the preceding claims, wherein X is S, R¹ is H and R² is H.

16. A benzazole derivative according to any of the preceding claims selected from the following group:


- 35 1,3-benzothiazol-2-yl(2-chloro-4-pyrimidinyl)-acetonitrile
1,3-benzothiazol-2-yl(2,6-dimethoxy-4-pyrimidinyl)acetonitrile
1,3-benzothiazol-2-yl[3-chloro-5-(trifluoromethyl)-2-pyridinyl]acetonitrile
1,3-benzothiazol-2-yl(2-chloro-6-methyl-4-pyrimidinyl)acetonitrile
1,3-benzothiazol-2-yl[2-(methylsulfanyl)-4-pyrimidinyl]acetonitrile
1,3-benzothiazol-2-yl(6-chloro-5-nitro-4-pyrimidinyl)acetonitrile
40 1,3-benzothiazol-2-yl(2-pyrimidinyl)acetonitrile
1,3-benzothiazol-2-yl(2-oxo-2,3-dihydro-4-pyridinyl)acetonitrile
1,3-benzothiazol-2-yl(2-phenyl-4-quinazolinyl)acetonitrile
(6-chloro-1,3-benzothiazol-2-yl)(phenyl)acetonitrile
1,3-benzothiazol-2-yl(5-chloro-2-pyridinyl)acetonitrile
45 1,3-benzothiazol-2-yl(phenyl)acetonitrile
1,3-benzothiazol-2-yl(6-chloro-2-pyridinyl)acetonitrile
1,3-benzothiazol-2-yl(2-pyrazinyl)acetonitrile
1,3-benzothiazol-2-yl(2-[(1H-imidazol-4-yl)ethyl]amino)-4-pyrimidinyl]acetonitrile
1,3-benzothiazol-2-yl[2-(1-piperazinyl)-4-pyrimidinyl]acetonitrile
50 1,3-benzothiazol-2-yl[2-(4-benzyl-1-piperidinyl)-4-pyrimidinyl]acetonitrile
1,3-benzothiazol-2-yl[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]acetonitrile
1,3-benzothiazol-2-yl[2-(4-morpholinyl)-4-pyrimidinyl]acetonitrile
1,3-benzothiazol-2-yl[2-(methylamino)-4-pyrimidinyl]acetonitrile
1,3-benzothiazol-2-yl[2-{4-[2-(4-morpholinyl)ethyl]-1-piperazinyl}-4-pyrimidinyl]acetonitrile
55 1,3-benzothiazol-2-yl[2-(4-benzyloxy-1-piperidinyl)-4-pyrimidinyl]acetonitrile
1,3-benzothiazol-2-yl[2-(4-hydroxy-1-piperidinyl)-4-pyrimidinyl]acetonitrile
1,3-benzothiazol-2-yl(2-hydrazino-4-pyrimidinyl)acetonitrile
1,3-benzothiazol-2-yl(2-[(dimethylamino)ethyl]amino)-4-pyrimidinyl]acetonitrile

1,3-benzothiazol-2-yl[2-(dimethylamino)-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[(2-methoxyethyl)amino]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[(2-hydroxyethyl)amino]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-(propylamino)-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[(3-(1H-imidazol-1-yl)propyl)amino]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-(1-pyrrolidinyl)-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[(2-phenylethyl)amino]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[(2-pyridinylmethyl)amino]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[4-(1H-1,2,3-benzotriazol-1-yl)-1-piperidinyl]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[4-(2-pyrazinyl)-1-piperazinyl]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[4-(2-pyrimidinyl)-1-piperazinyl]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[(2-(3-pyridinyl)ethyl)amino]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[5-bromo-2-[(2-(dimethylamino)ethyl)amino]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-(methoxy-4-pyrimidinyl)acetonitrile
 (2-chloro-4-pyrimidinyl)(3-methyl-1,3-benzothiazol-2(3H)-ylidene)ethanenitrile
 1,3-benzothiazol-2-yl[2-(methylsulfanyl)-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-(chloro-4-pyrimidinyl)acetonitrile
 1,3-benzothiazol-2-yl[2-(methylamino)-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[(2-(1H-imidazol-4-yl)ethyl)amino]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[(2-hydroxyethyl)amino]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-(methoxy-4-pyrimidinyl]acetonitrile

17. A benzazole derivative according to claim 16, which is selected from the group consisting of:

1,3-benzothiazol-2-yl[2-(methylsulfanyl)-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-(chloro-4-pyrimidinyl)acetonitrile
 1,3-benzothiazol-2-yl[2-(methylamino)-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[(2-(1H-imidazol-4-yl)ethyl)amino]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-[(2-hydroxyethyl)amino]-4-pyrimidinyl]acetonitrile
 1,3-benzothiazol-2-yl[2-(methoxy-4-pyrimidinyl]acetonitrile

18. Use of a benzazole derivatives according to formula I



I

as well as its tautomers, its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

X is O, S or NR⁰, with R⁰ being H or an unsubstituted or substituted C₁-C₆ alkyl;

G is selected from the group comprising or consisting of unsubstituted or substituted aryl or heteroaryl substituents, unsubstituted or substituted 3-8-membered saturated or unsaturated ring systems containing at least one heteroatom selected from N, O or S; said 3-8-membered ring system may be fused with a substituted or unsubstituted aryl or heteroaryl system thus providing a bicyclic system;

R¹ is selected from the group comprising or consisting of hydrogen, unsubstituted or substituted C₁-C₆-alkoxy, unsubstituted or substituted C₁-C₆-thioalkoxy, unsubstituted or substituted C₁-C₆-alkyl, unsubstituted or sub-

stituted C₂-C₆-alkenyl, unsubstituted or substituted C₂-C₆-alkynyl, primary, secondary or tertiary amino groups, aminoacyl, aminocarbonyl, unsubstituted or substituted C₁-C₆ alkoxycarbonyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, sulfonyl, sulfonamide, unsubstituted or substituted hydrazides;

R² is selected from the group comprising or consisting of hydrogen, unsubstituted or substituted C₁-C₆-alkyl, unsubstituted or substituted C₂-C₆-alkenyl, unsubstituted or substituted C₂-C₆-alkynyl, unsubstituted or substituted C₁-C₆-alkyl-aryl, unsubstituted or substituted aryl or heteroaryl, unsubstituted or substituted C₁-C₆-alkyl-heteroaryl, C(O)-OR³, -C(O)-R³, -C(O)-NR³R^{3'}, -(SO₂)R³, with

R³ and R^{3'} being independently selected from the group comprising or consisting of hydrogen, unsubstituted or substituted C₁-C₆ alkyl, unsubstituted or substituted C₂-C₆ alkenyl, unsubstituted or substituted C₂-C₆ alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted C₁-C₆-alkyl aryl, unsubstituted or substituted C₁-C₆-alkyl heteroaryl,

for the preparation of a pharmaceutical composition for the modulation of the JNK pathway.

19. Use according to claim 18 for the treatment or prevention of disorders associated with the abnormal expression or activity of JNK.

20. Use according to claim 19 for the treatment or prevention of disorders associated with the abnormal expression or activity of JNK2 and/or 3.

21. Use according to any of claims 19 to 20 for the treatment of neuronal disorders including epilepsy; Alzheimer's disease, Parkinson's disease, retinal disease, spinal cord injury, head trauma.


22. Use according to any of claims 19 to 20 for the treatment of autoimmune diseases including Multiple Sclerosis, inflammatory bowel disease (IBD), rheumatoid arthritis, asthma, septic shock, transplant rejection.

23. Use according to any of claims 19 to 20 for the treatment of cancer including breast-, colorectal, pancreatic cancer.

24. Use according to any of claims 19 to 20 for the treatment of cardiovascular diseases including stroke, arteriosclerosis, myocardial infarction, myocardial reperfusion injury.


25. A pharmaceutical composition containing at least one benzazole derivative according to any of the claims 2 to 17 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

26. Process for the preparation of a benzazole derivative according to any of claims 1 to 17, wherein the following reaction is performed :



whereby X and G are as above described and Y, Y' are suitable leaving groups like halogen.

27. Process according to claim 26, wherein the following reactions are performed :



with R^1 , R^2 , Y and X being as described above.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 81 1207

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	BIEHL E R AT AL: "LDA (lithium diisopropylamide) mediated reactions of 1-naphthalynes with lithiated acetonitriles and 1,4-dipolar nucleophilic anions" SYNTHESIS, no. 9, September 1993 (1993-09), pages 885-888, XP002138990 * page 886, compounds 13, 14 *	1,3-8,26	C07D277/64 C07D263/56 C07D235/16 C07D417/06 C07D417/14 C07D413/06 C07D403/06 A61K31/4184 A61K31/428 A61K31/423 A61P25/00
X	US 2 918 369 A (DOORENBOS N J ET AL) 22 December 1959 (1959-12-22) * example XIII *	1,3-8,15	
X	DE 26 17 345 A (FUJI PHOTO FILM CO., LTD.) 4 November 1976 (1976-11-04) * examples 26,34 *	1,3-8	
X	HUNGER A ET AL: "Benzimidazol-Derivate und verwandte Heterocyclen VI) Synthese von Pheny-'1-aminoalkyl-benzimidazolyl-(2)-essigsäure-estern und amiden" HELVETICA CHIMICA ACTA, vol. 43, no. 6, 17 October 1960 (1960-10-17), pages 1727-1733, XP002138991 * page 1728, compounds III and VI, page 1730, table 2 *	1,3-8	TECHNICAL FIELDS SEARCHED (Int.Cl.7) C07D A61K A61P
X	EP 0 364 765 A (BAYER AG) 25 April 1990 (1990-04-25) * pages 18-20, 32, 33 *	1,3-8,15	
-/--			
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 30 May 2000	Examiner Allard, M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons S : member of the same patent family, corresponding document</p>			

EPC FORM 152 (3.92) (IP/C01)

European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 81 1207

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	BIEHL E R AT AL: "LDA (lithium diisopropylamide) mediated reactions of 1-naphthalynes with lithiated acetonitriles and 1,4-dipolar nucleophilic anions" SYNTHESIS, no. 9, September 1993 (1993-09), pages 885-888, XP002138990 * page 886, compounds 13, 14 *	1,3-8,26	C07D277/64 C07D263/56 C07D235/16 C07D417/06 C07D417/14 C07D413/06 C07D403/06 A61K31/4184 A61K31/428 A61K31/423 A61P25/00
X	US 2 918 369 A (DOORENBOS N J ET AL) 22 December 1959 (1959-12-22) * example XIII *	1,3-8,15	
X	DE 26 17 345 A (FUJI PHOTO FILM CO., LTD.) 4 November 1976 (1976-11-04) * examples 26,34 *	1,3-8	
X	HUNGER A ET AL: "Benzimidazol-Derivate und verwandte Heterocyclen VI) Synthese von Pheny-'1-aminoalkyl-benzimidazolyl-(2)!-essigsäure-estern und amiden" HELVETICA CHIMICA ACTA, vol. 43, no. 6, 17 October 1960 (1960-10-17), pages 1727-1733, XP002138991 * page 1728, compounds III and VI, page 1730, table 2 *	1,3-8	TECHNICAL FIELDS SEARCHED (Int.Cl.7) C07D A61K A61P
X	EP 0 364 765 A (BAYER AG) 25 April 1990 (1990-04-25) * pages 18-20, 32, 33 *	1,3-8,15	
-/-			
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 30 May 2000	Examiner Allard, M
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons S : member of the same patent family, corresponding document	

EPC FORM 1503 03/02 (pre-C01)

EP 1 110 957 A1



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 81 1207

DOCUMENTS CONSIDERED TO BE RELEVANT			Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages			
X	HUANG Z T ET AL: "Synthesis, reactions, and tautomerism of ketene N,S-acetals with benzothiazoline ring" CHEMISCHE BERICHTE, vol. 123, no. 3, March 1990 (1990-03), pages 541-547, XP002138992 * page 545, compound 3h *	1,3-8, 15,16		
X	CHEMICAL ABSTRACTS, vol. 117, no. 23, 7 December 1992 (1992-12-07) Columbus, Ohio, US; abstract no. 233799s, VOLOVENKO Y M ET AL: "Synthesis and biological activity of alpha-substituted 2-pyridylacetonitriles" page 850; XP002138993 * abstract * & UKR. KHIM. ZH. (RUSS. ED.), vol. 58, no. 5, 1992, pages 430-432.	1-8,15		
X	DATABASE CROSSFIRE 'Online! Beilstein Institut fuer Literatur der organischen Chemie XP002138996 * Beilstein Registry Number 1128326 * & JUSTUS LIEBIGS ANN. CHEM., 1978, pages 473-511.	1,3-8		
X	DATABASE CROSSFIRE 'Online! Beilstein Institut fuer Literatur der organischen Chemie XP002138997 * Beilstein Registry Number 5395626, 5395012, 5395000 and 5392953 * & ZH. ORG. KHIM., vol. 1, 1965, pages 756-762.	1,3-8,15		
The present search report has been drawn up for all claims				
Place of search THE HAGUE		Date of completion of the search 30 May 2000	Examiner Allard, M	
CATEGORY OF CITED DOCUMENTS			T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document				



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 81 1207

DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)	
X	DATABASE CROSSFIRE 'Online! Beilstein Institut fuer Literatur der organischen Chemie XP002138998 * Beilstein Registry Number 5589714, 5589715, 5589716, 5589718, 5589719, 5589720, 5589721, 5589722, 5589723 and 5601864 * & J. PRAKT. CHEM., vol. 324, no. 1, 1982, pages 3-11, ---	1,3-8,15		
X	DATABASE CROSSFIRE 'Online! Beilstein Institut fuer Literatur der organischen Chemie XP002138999 * Beilstein Registry Number 855092, 861654 and 874268 * & ZH. ORG. KHIM., vol. 15, 1979, page 200 ---	1,3-8		
X	DATABASE CROSSFIRE 'Online! Beilstein Institut fuer Literatur der organischen Chemie XP002139000 * Beilstein Registry Numbers 3616387 and 3614951 * & HETEROCYCLES, vol. 31, no. 6, 1990, pages 1115-1127, ---	1,3-8		TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	DATABASE CROSSFIRE 'Online! Beilstein Institut fuer Literatur der organischen Chemie XP002139001 * Beilstein Registry Number 6226072, 6220826, 6220828, 6235458, 6231468 and 6231469 * & J.PRAKT. CHEM., vol. 330, no. 4, 1988, pages 590-606, --- -/--	1,3-8,15		
The present search report has been drawn up for all claims				
Place of search THE HAGUE		Date of completion of the search 30 May 2000	Examiner Allard, M	
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document		

EPO FORM 1503 (03.02) (P4/C01)

European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 81 1207

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	DATABASE CROSSFIRE 'Online! Beilstein Institut fuer Literatur der organischen Chemie XP002139002 * Beilstein Registry Number 5115381, 5130108, 5161287 and 5169755 * & KHIM. GETEROTSIKL. SOEDIN., vol. 8, 1988, pages 1119-1123, ---	1,3-8	
D,X	DATABASE WPI Section Ch, Week 199923 Derwent Publications Ltd., London, GB; Class B02, AN 1999-266966 XP002139004 -& JP 11 080155 A (TOA FOOD CHEM CO LTD), 26 March 1999 (1999-03-26) * abstract *	18-20,24	
X	CHEMICAL ABSTRACTS, vol. 126, no. 6, 10 February 1997 (1997-02-10) Columbus, Ohio, US; abstract no. 74791a, HASSAN A A ET AL: "Reaction of benzimidazolylacetonitrile and -methanethiol with electron defficient compounds" page 583; XP002138994 * abstract * -& CHEMICAL ABSTRACTS, vol. 126, no. 1, 1 January 1997 (1997-01-01) Columbus, Ohio, US; FORMULA INDEX: page 1990F; XP002138995 * Compound with formula C15H8C13N3O2 * & HETEROCYCL. COMMUN., vol. 2, no. 5, 1996, pages 441-446, --- -/--	1,3-8	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 30 May 2000	Examiner Allard, M
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1503 03/02 (No.001)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 81 1207

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D,X	DATABASE CHEMICAL ABSTRACTS 'Online! Chemical Abstracts Services, Columbus, Ohio, US AN 117-233221: XP002139003 * Registry Number 144061-99-4, 144061-98-3, 144061-97-2, 144061-96-1, 144061-95-0 and 92498-43-6 * & HETEROCYCLES, vol. 34, no. 6, 1992, pages 1239-1249, ----	1,3-8	
A	WO 99 21859 A (GLAXO GROUP LIMITED) 6 May 1999 (1999-05-06) * claims 1,25,26 *	1,18	
A	MARONEY A C ET AL: "Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway" JOURNAL OF NEUROSCIENCE, vol. 18, no. 1, 1 January 1998 (1998-01-01), pages 104-111-111, XP000870100 ISSN: 0270-6474 * the whole document *	1,18	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Place of search THE HAGUE		Date of completion of the search 30 May 2000	Examiner Allard, M
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03/02 (P44C011)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 81 1207

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information

30-05-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2918369 A	22-12-1959	NONE	
DE 2617345 A	04-11-1976	JP 51123223 A GB 1541936 A	27-10-1976 14-03-1979
EP 364765 A	25-04-1990	AU 617537 B AU 4246289 A BR 8905104 A CA 2000234 A CS 8905679 A DD 288380 A DK 494589 A HU 54358 A, B JP 2164873 A NZ 230925 A US 4933341 A US 5196562 A ZA 8907614 A	28-11-1991 21-06-1990 15-05-1990 08-04-1990 12-09-1990 28-03-1991 09-04-1990 28-02-1991 25-06-1990 26-07-1991 12-06-1990 23-03-1993 24-12-1991
JP 11080155 A	26-03-1999	NONE	
WO 9921859 A	06-05-1999	AU 1151099 A	17-05-1999

EPOFORM P459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82